Skip to main content
Editas Medicine, Inc. logo

Editas Medicine, Inc. — Investor Relations & Filings

Ticker · EDIT ISIN · US28106W1036 LEI · 5299000AON4Q9NT2JE42 US Professional, scientific and technical activities
Open in API
Filings indexed 679 across all filing types
Latest filing 2018-06-19 Director's Dealing
Country US United States of America
Listing US EDIT

About Editas Medicine, Inc.

https://www.editasmedicine.com/

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing transformative medicines for serious diseases using CRISPR technology. The company's mission is to discover, develop, and commercialize durable, precision genomic therapies that can correct the underlying genetic causes of various conditions. Its proprietary platform enables the precise revision, removal, or replacement of DNA. Editas Medicine's research and development pipeline is concentrated on creating both in vivo (in-body) and ex vivo (out-of-body) gene-edited medicines to treat a broad class of diseases, with a focus on rare genetic disorders.

Recent filings

Filing Released Lang Actions
FORM 4 -
Director's Dealing
2018-06-19 English
FORM 4 -
Director's Dealing
2018-06-19 English
FORM 4 -
Director's Dealing
2018-06-19 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 15, 2018. The key content is the submission of matters to a vote of security holders at the Annual Meeting of Stockholders, including election of directors and ratification of the independent auditor. The document provides detailed voting results for these matters. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document is not an Annual Report, Audit Report, or Management Report, nor is it a proxy solicitation or presentation. It is also not a report publication announcement or a regulatory filing of a different nature. The length is under 5,000 characters and contains substantive voting results, so it is not merely an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2018-06-19 English
FORM 4 -
Director's Dealing
2018-06-15 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 8, 2018. It reports the registration for resale of shares pursuant to a prospectus supplement under an automatic shelf registration statement on Form S-3. The document includes legal opinions and consents related to the validity of the shares. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document is a current report disclosing a specific event related to capital structure (registration of shares for resale). This fits the category of Capital/Financing Update (CAP). The document length is 3550 characters, which is short but contains substantive information about a financing-related event, not merely an announcement of a report or certification. Therefore, the best classification is CAP with high confidence.
2018-06-08 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.